Drug intelligence / Profile preview

MNC101

Development stage: Preclinical
Lead developer: NeuroCure
Modality: Peptides
Administration: Subcutaneous

Overview

MNC101 is a novel peptide fragment derived from Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) being developed by MyNeuroCure for the treatment of Amyotrophic Lateral Sclerosis (ALS). The drug exhibits a dual mechanism of action: it modulates the Unfolded Protein Response (UPR) to alleviate endoplasmic reticulum (ER) stress and inhibits the synthesis and release of pro-inflammatory cytokines. Designed to be blood-brain barrier (BBB) penetrant, MNC101 is administered via subcutaneous injection. It is currently in preclinical development for ALS and Multiple Sclerosis, with discovery-stage programs targeting Parkinson's disease and Diabetes Mellitus.

Other names: MANF fragmentMesencephalic Astrocyte-derived Neurotrophic Factor fragment

Targets

MANF (Mesencephalic astrocyte-derived neurotrophic factor)

Beyond the preview

Go deeper on MNC101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MNC101.

Explore the full profile